Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
- F. Mahon, D. Réa, P. Rousselot
- MedicineThe Lancet Oncology
- 1 November 2010
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
- S. Saussele, J. Richter, F. Mahon
- MedicineThe Lancet Oncology
- 1 June 2018
Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable…
- P. Rousselot, A. Charbonnier, F. Mahon
- MedicineJournal of Clinical Oncology
- 10 February 2014
Loss of MMR is a practical and safe criterion for restarting therapy in patients with CML with prolonged CMR, and should be a criterion for resuming therapy.
Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
- C. Preudhomme, J. Guilhot, F. Guilhot
- Medicine, BiologyNew England Journal of Medicine
- 22 December 2010
As compared with other treatments, the addition of peginterferon alfa-2a to imatinib therapy resulted in significantly higher rates of molecular response in patients with chronic-phase CML.
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
- J. Hasford, M. Baccarani, R. Hehlmann
- Medicine, PsychologyBlood
- 21 July 2011
A new prognostic score that is superior to the Sokal and Euro scores both in its prognostic ability and in its simplicity is described, which can be used to identify CML patients with significantly lower probabilities of responding to therapy and survival, thus alerting physicians to those patients who require closer observation and early intervention.
Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods
- L. Karayan‐Tapon, V. Quillien, C. Gratas-Rabbia-Ré
- MedicineJournal of Neuro-Oncology
- 1 May 2010
Results confirm the prognostic value of MGMT promoter methylation in glioblastoma patients initially treated with TMZ, with SQ-MSP allowed better discrimination than classical MSP, and pyrosequencing represented a good option.
Clinical and Biological Features at Diagnosis in 40 Children With Chronic Myeloid Leukemia
- F. Millot, P. Traore, F. Guilhot
- MedicinePediatrics
- 1 July 2005
It is shown that the characteristics of CML seem to differ in children compared with previously published adult series; in particular, the presenting leukocyte counts are often higher in children.
Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
- G. Étienne, J. Guilhot, F. Mahon
- MedicineJournal of Clinical Oncology
- 20 January 2017
With a median follow-up of more than 6 years after treatment discontinuation, the STIM1 study demonstrates that IM can safely be discontinued in patients with a sustained deep molecular response with no late MR.
Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
- F. Bonifazi, A. de Vivo, M. Baccarani
- Medicine, BiologyBlood
- 15 November 2001
It is pointed out that a substantial long-term survival in CCgRs is restricted mainly to low-risk and possibly intermediate- risk patients and occurs significantly less often in high-risk patients.
Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial
- D. Payen, J. Guilhot, R. Robert
- Medicine, BiologyIntensive Care Medicine
- 11 April 2015
This multicenter randomized controlled study demonstrated a non-significant increase in mortality and no improvement in organ failure with PMX HP treatment compared to conventional treatment of peritonitis-induced SS.
...
...